STAGE IV LUNG CANCER AJCC V8

This early-stage study is testing the safety of a personalized vaccine designed to train a patient's immune system to attack their specific cancer. It is for adults with advanced breast cancer, melanoma, or non-small cell lung cancer that has continued to grow despite standard tr…

This study is testing if adding diclofenac, a common anti-inflammatory painkiller, can help control advanced lung cancer that is starting to get worse while patients are on standard immunotherapy. The goal is to see if diclofenac can slow tumor growth and make the immunotherapy w…

This small, early-stage study is testing whether a portable device that creates electric fields is safe and practical for people with breast or lung cancer that has spread to the lining of the spinal cord. Participants wear the device on their back for most of the day, aiming to …

This study is testing whether adding a new drug called GT103 to an existing immunotherapy (pembrolizumab) can better control advanced lung cancer that has a specific genetic change (STK11 mutation). The trial is for patients whose cancer has continued to grow despite prior treatm…

This study is for people with advanced non-small cell lung cancer that has worsened after initial chemotherapy and immunotherapy. It compares the current standard two-drug treatment (docetaxel and ramucirumab) against that same treatment plus a third drug called cemiplimab, which…

This study is testing whether updating radiation treatment plans at set times during therapy can reduce damage to healthy heart and lung tissue in people with non-small cell lung cancer. Researchers want to see if this adaptive approach lowers side effects like lung inflammation …

This study aims to find the best radiation method for treating cancer that has spread to the brain. It compares giving one large radiation dose versus spreading the same total radiation over three smaller treatments. Researchers want to see which approach better controls the brai…

This early study is testing if adding a low-dose immune stimulant (IL-2) to a standard immunotherapy drug (pembrolizumab) can better fight advanced non-small cell lung cancer. The main goal is to see how this combination changes the patient's immune cells. Researchers will also c…

This study is testing two different combinations of targeted drugs for people with advanced non-small cell lung cancer that has specific genetic changes (EGFR and MET) and has stopped responding to a common treatment. The trial will compare whether adding a third drug (ramuciruma…

This study is testing if adding a second drug, ramucirumab, to the standard drug tepotinib works better for people with advanced non-small cell lung cancer that has a specific genetic change called a MET exon 14 skip. The goal is to see if the combination can better control the c…

This early-stage study is testing a new combination of two drugs, osimertinib and tegavivint, for people with a specific type of advanced lung cancer that has spread. The main goal is to find the safest and most effective dose of the drug pair. Researchers will also check if the …

This study is for people with a specific type of advanced lung cancer that has spread and has an EGFR gene change. It compares a standard drug (osimertinib) alone against that same drug combined with a second drug (bevacizumab). The goal is to see if the two-drug combination can …

This study tests whether combining a specialized radiation technique called grid therapy with standard immunotherapy can help control advanced lung cancer that has worsened despite current treatments. Grid therapy delivers high radiation doses to small tumor areas, potentially ki…

This study is testing a specialized radiation technique for patients with breast or lung cancer that has spread to the fluid around the brain and spine. The goal is to see if precisely targeting the entire brain and spinal cord with radiation, while avoiding a key memory area, ca…

This study compares two radiation treatments for patients whose small cell lung cancer has spread to the brain. One method targets only the tumors with high precision, while the other treats the whole brain but avoids the memory center. The main goal is to see which approach bett…

This study is for people with extensive-stage small cell lung cancer that has spread. It tests whether adding a new oral drug called iadademstat to standard immunotherapy maintenance treatment can help control the cancer and prevent it from growing for a longer period. The first …

This study is testing an oral medication called avapritinib for people with advanced solid tumors that have spread and have specific genetic changes (mutations in the CKIT or PDGFRA genes). The drug aims to block the signals that help these tumor cells grow, potentially controlli…

This study is testing if a new drug, SX-682, works better when given with an existing immunotherapy drug (pembrolizumab) for people with advanced non-small cell lung cancer that has spread or come back. The goal is to see if this combination can help the body's immune system figh…

This study is testing whether combining two targeted cancer drugs is safe and effective for people with advanced non-small cell lung cancer that has a specific genetic change called KRAS G12C. The trial is for patients whose cancer has continued to grow despite previous treatment…

This study is testing a new, personalized vaccine designed to target the unique proteins on a patient's own cancer cells. It is being given alongside an existing immunotherapy drug (pembrolizumab) to see if the combination is safe and can help control advanced solid tumors that h…

This early-stage trial is testing a new combination of two immunotherapy drugs, PBF-1129 and nivolumab, for people with advanced non-small cell lung cancer that has returned or spread. The main goal is to find the safest dose and understand the side effects. Researchers also want…

This study is testing if a combination of two drugs can help control advanced small cell lung cancer that has returned or spread after initial treatment. It will involve about 56 adults whose cancer has progressed after standard chemo-immunotherapy. The goal is to see if adding a…

This early-stage study is testing a drug called gilteritinib in patients with advanced, ALK-positive non-small cell lung cancer that has stopped responding to other targeted treatments. The main goals are to find the safest dose and understand the side effects. Researchers are st…

This study is for people with breast or non-small cell lung cancer that has spread to the fluid-filled space around the brain and spinal cord. It compares two types of radiation therapy to see which one helps patients live longer. One method targets only the specific areas causin…

This early-stage study is testing a new combination of two drugs, vismodegib and atezolizumab, for adults with advanced non-small cell lung cancer that has come back or spread. The main goal is to find the safest dose and understand the side effects of using these drugs together.…

This study is for adults 70 and older with advanced non-small cell lung cancer. It compares two treatment approaches: immunotherapy alone versus immunotherapy combined with chemotherapy. The main goal is to see if the combination helps patients live longer and better control thei…

This study is testing a specialized radiation treatment for patients whose breast or lung cancer has spread to the fluid surrounding the brain and spinal cord. The treatment aims to target all areas where this type of cancer spread might occur. Researchers want to see if this app…

This study is testing a new imaging dye that attaches to lung cancer cells and glows under a special camera. The goal is to help surgeons see the cancer more clearly during an operation, which could help them remove all of the cancer while leaving more healthy tissue. The trial w…

This early-stage study aims to find out if it is safe to give palliative radiation therapy at the same time as a cancer drug called lurbinectedin. The trial is for adults with extensive stage small cell lung cancer that has spread and worsened after initial chemotherapy. Research…

This study is testing whether a yoga program for patients and their caregivers can improve physical function and quality of life during radiation treatment for lung or esophageal cancer. It will compare yoga sessions to educational sessions to see which helps patients walk farthe…

This study is testing whether a special communication tool helps doctors and patients with non-small cell lung cancer make treatment decisions together more effectively. The tool guides conversations about treatment options, benefits, and risks while considering each patient's pe…

This study aims to better understand cancer cachexia, the severe weight and muscle loss that often occurs with advanced cancers. Researchers will observe 800 patients with advanced colorectal, lung, or pancreatic cancer to identify different patterns or 'subtypes' of this conditi…

This study is testing a new screening tool designed to help patients with advanced lung cancer better understand their illness and communicate their care preferences. Researchers will compare the tool against usual care for 100 patients to see if it leads to more informed discuss…

This study aims to understand why some patients with advanced cancers like melanoma and lung cancer respond well to a common immunotherapy (anti-PD-1), while others do not. Researchers will collect blood samples from 500 patients to measure specific markers in immune cells during…

This study aims to find out how common insomnia is in people whose lung cancer has spread to other parts of the body. Researchers will review medical records and ask 60 participants to complete a sleep questionnaire. The goal is to better understand this specific symptom burden i…

This study aims to learn how advanced lung cancer responds to a combination of chemotherapy, immunotherapy, and radiation by closely watching changes on PET/CT scans. It will enroll 80 patients with stage IV non-small cell lung cancer who are starting this standard treatment. The…

This study is collecting tissue and blood samples from cancer patients over time to create a research resource called a biobank. Researchers will analyze these samples to understand how cancer changes during treatment and why some treatments stop working. The goal is to help scie…

This study aims to understand why some cancer patients develop severe diarrhea and colon inflammation (colitis) while taking powerful immunotherapy drugs called immune checkpoint inhibitors. Researchers will collect stool, blood, and tissue samples from 800 patients with melanoma…